Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

555 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lead optimisation of OXS007417: in vivo PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia.
Cogswell TJ, Josa-Culleré L, Zimmer D, Galan SRG, Jay-Smith M, Harris KS, Bataille CJR, Jackson TR, Zhang D, Davies SG, Vyas P, Milne TA, Wynne GM, Russell AJ. Cogswell TJ, et al. Among authors: vyas p. RSC Med Chem. 2024 Jul 22;15(10):3495-506. doi: 10.1039/d4md00275j. Online ahead of print. RSC Med Chem. 2024. PMID: 39220761 Free PMC article.
Phenotypic screening identifies a trisubstituted imidazo[1,2-a]pyridine series that induces differentiation in multiple AML cell lines.
Josa-Culleré L, Galan SRG, Cogswell TJ, Jackson TR, Jay-Smith M, Mola L, Greaves CR, Carter TS, Madden KS, Trott S, Zhang D, Bataille CJR, Davies SG, Vyas P, Milne TA, Naylor A, Wynne GM, Russell AJ. Josa-Culleré L, et al. Among authors: vyas p. Eur J Med Chem. 2023 Oct 5;258:115509. doi: 10.1016/j.ejmech.2023.115509. Epub 2023 May 26. Eur J Med Chem. 2023. PMID: 37343464
Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging.
Jakobsen NA, Turkalj S, Zeng AGX, Stoilova B, Metzner M, Rahmig S, Nagree MS, Shah S, Moore R, Usukhbayar B, Angulo Salazar M, Gafencu GA, Kennedy A, Newman S, Kendrick BJL, Taylor AH, Afinowi-Luitz R, Gundle R, Watkins B, Wheway K, Beazley D, Murison A, Aguilar-Navarro AG, Flores-Figueroa E, Dakin SG, Carr AJ, Nerlov C, Dick JE, Xie SZ, Vyas P. Jakobsen NA, et al. Among authors: vyas p. Cell Stem Cell. 2024 Aug 1;31(8):1127-1144.e17. doi: 10.1016/j.stem.2024.05.010. Epub 2024 Jun 24. Cell Stem Cell. 2024. PMID: 38917807 Free PMC article.
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.
Russell NH, Thomas A, Hills RK, Thomas I, Gilkes A, Almuina NM, Burns S, Marsh L, Vyas P, Metzner M, McCarthy N, Andrew G, Byrne J, Sellar RS, Kelly R, Cahalin P, Overgaard UM, Mehta P, Dennis M, Knapper S, Freeman SD. Russell NH, et al. Among authors: vyas p. J Clin Oncol. 2024 Nov 18:JCO2400259. doi: 10.1200/JCO.24.00259. Online ahead of print. J Clin Oncol. 2024. PMID: 39556780
555 results